Thermo Fisher Scientific reported first-quarter 2026 results on April 23, with total revenue of $11.01 billion, up 6% year-on-year. Inside the Analytical Instruments segment - the slice most directly relevant for the process-analytics buyer - revenue was $1.716 billion, flat in headline terms and down 2% on an organic basis.
In the release, the company attributed the segment’s organic decline to lower demand from academic and government customers; CEO Marc Casper described the broader quarter as “a strong start to the year, reflecting excellent execution.” Adjusted operating margin for Analytical Instruments came in at 20.7%, down 250 basis points year-on-year, with management pointing to tariffs and FX as the dominant drag and unfavourable mix as a secondary factor. The segment launched three flagship instruments during the quarter: the Glacios 3 cryo-TEM, the TSQ Certus triple-quadrupole mass spectrometer (positioned for pharmaceutical and applied markets), and the Niton XL5e handheld XRF analyser. Group-level GAAP diluted EPS was $4.43, up 11%; adjusted EPS was $5.44, up 6%. Full-year 2026 revenue guidance was raised to a range of $47.3-48.1 billion, with adjusted EPS of $24.64-25.12.
For process-analytics buyers, the readthrough is mixed. The pharmaceutical and applied-markets pull - the part of Analytical Instruments closest to PAT spend - remains the structural growth engine, but academic and government softness is masking that in segment headline numbers, and the TSQ Certus positioning signals continued vendor focus on QC and release-testing workflows. Buyers benchmarking process Raman or NIR analyser pricing against Thermo’s catalogue (see our Raman vs NIR decision framework) should not read flat segment revenue as a signal about the inline-analyser line specifically; segment-level reporting does not disaggregate process instruments from cryo-EM or XRF.